

Alan F List

List of Publications by Citations

Source: <https://exaly.com/author-pdf/3183988/alan-f-list-publications-by-citations.pdf>

Version: 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

28

papers

5,195

citations

20

h-index

30

g-index

30

ext. papers

6,069

ext. citations

9.5

avg, IF

4.81

L-index

#	Paper	IF	Citations
28	Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. <i>Lancet Oncology, The</i> , 2009 , 10, 223-32	21.7	1961
27	Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. <i>New England Journal of Medicine</i> , 2006 , 355, 1456-65	59.2	1029
26	Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs. <i>Blood</i> , 2008 , 112, 45-52	2.2	454
25	Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System. <i>Cancer</i> , 2008 , 113, 1351-61	6.4	386
24	Induction of myelodysplasia by myeloid-derived suppressor cells. <i>Journal of Clinical Investigation</i> , 2013 , 123, 4595-611	15.9	187
23	The NLRP3 inflammasome functions as a driver of the myelodysplastic syndrome phenotype. <i>Blood</i> , 2016 , 128, 2960-2975	2.2	162
22	Inhibition of the TGF-beta receptor I kinase promotes hematopoiesis in MDS. <i>Blood</i> , 2008 , 112, 3434-43	2.2	140
21	An international consortium proposal of uniform response criteria for myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in adults. <i>Blood</i> , 2015 , 125, 1857-65	2.2	118
20	GM-CSF-dependent pSTAT5 sensitivity is a feature with therapeutic potential in chronic myelomonocytic leukemia. <i>Blood</i> , 2013 , 121, 5068-77	2.2	116
19	Reduced SMAD7 leads to overactivation of TGF-beta signaling in MDS that can be reversed by a specific inhibitor of TGF-beta receptor I kinase. <i>Cancer Research</i> , 2011 , 71, 955-63	10.1	96
18	The central role of inflammatory signaling in the pathogenesis of myelodysplastic syndromes. <i>Blood</i> , 2019 , 133, 1039-1048	2.2	90
17	Robust patient-derived xenografts of MDS/MPN overlap syndromes capture the unique characteristics of CMML and JMML. <i>Blood</i> , 2017 , 130, 397-407	2.2	88
16	A Multi-Institution Phase I Trial of Ruxolitinib in Patients with Chronic Myelomonocytic Leukemia (CMML). <i>Clinical Cancer Research</i> , 2016 , 22, 3746-54	12.9	65
15	Unraveling the Pathogenesis of MDS: The NLRP3 Inflammasome and Pyroptosis Drive the MDS Phenotype. <i>Frontiers in Oncology</i> , 2016 , 6, 151	5.3	50
14	When clinical heterogeneity exceeds genetic heterogeneity: thinking outside the genomic box in chronic myelomonocytic leukemia. <i>Blood</i> , 2016 , 128, 2381-2387	2.2	40
13	Poor outcome of patients with myelodysplastic syndrome after azacitidine treatment failure. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2013 , 13, 711-5	2	39
12	Heterogeneous expression of cytokines accounts for clinical diversity and refines prognostication in CMML. <i>Leukemia</i> , 2019 , 33, 205-216	10.7	30

11	Cytokine-Regulated Phosphorylation and Activation of TET2 by JAK2 in Hematopoiesis. <i>Cancer Discovery</i> , 2019 , 9, 778-795	24.4	26
10	Assessment of ASC specks as a putative biomarker of pyroptosis in myelodysplastic syndromes: an observational cohort study. <i>Lancet Haematology</i> , 2018 , 5, e393-e402	14.6	26
9	Reduced DOCK4 expression leads to erythroid dysplasia in myelodysplastic syndromes. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015 , 112, E6359-68	11.5	25
8	Pro-inflammatory proteins S100A9 and tumor necrosis factor- β suppress erythropoietin elaboration in myelodysplastic syndromes. <i>Haematologica</i> , 2017 , 102, 2015-2020	6.6	16
7	The clinical management of chronic myelomonocytic leukemia. <i>Clinical Advances in Hematology and Oncology</i> , 2014 , 12, 172-8	0.6	14
6	Phase I Clinical Trial of Selinexor in Combination with Daunorubicin and Cytarabine in Previously Untreated Poor-Risk Acute Myeloid Leukemia. <i>Clinical Cancer Research</i> , 2020 , 26, 54-60	12.9	11
5	Oxidized mitochondrial DNA released after inflammasome activation is a disease biomarker for myelodysplastic syndromes. <i>Blood Advances</i> , 2021 , 5, 2216-2228	7.8	10
4	Loss of Function of DOCK4 in Myelodysplastic Syndromes Stem Cells is Restored by Inhibitors of DOCK4 Signaling Networks. <i>Clinical Cancer Research</i> , 2019 , 25, 5638-5649	12.9	7
3	Integrated Human and Murine Clinical Study Establishes Clinical Efficacy of Ruxolitinib in Chronic Myelomonocytic Leukemia. <i>Clinical Cancer Research</i> , 2021 , 27, 6095-6105	12.9	4
2	SOHO State of the Art Update and Next Questions: Biology and Treatment of Myelodysplastic Syndromes. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017 , 17, 613-620	2	3
1	Dual pyroptotic biomarkers predict erythroid response in lower risk non-del(5q) myelodysplastic syndromes treated with lenalidomide and recombinant erythropoietin. <i>Haematologica</i> , 2021 ,	6.6	2